Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y, Kim JW, Penson RT, O’Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA […]
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a « real-life setting ».
van Wagensveld L, Colomban O, van der Aa MA, Freyer G, Sonke GS, Kruitwagen RFPM, You B.
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
Bouvarel B, Colomban O, Frenel JS, Loaec C, Bourgin C, Berton D, Freyer G, You B, Classe JM.
Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
Corbaux P, Freyer G, Glehen O, You B, Bakrin N, Gelot A, Dayde D, Sajous C, Piffoux M, Péron J, Lescuyer G, Payen L, Kepenekian V.
Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
Petiot F, Descargues P, Devouassoux-Shisheboran M, You B, Rousset-Jablonski C, Raffin D, Hajri T, Gertych W, Glehen O, Philip CA, Lamblin G, Golfier F, Bolze PA.
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
Morgan RD, Wang X, Barnes BM, Spurgeon L, Carrot A, Netto D, Hasan J, Mitchell C, Salih Z, Desai S, Shaw J, Winter-Roach B, Schlecht H, Burghel GJ, Clamp AR, Edmondson RJ, You B, Evans DGR, Jayson GC, Taylor SS.
Estimated Fetal Radiation Dose From 18 F-FDG PET/CT During the Second and Third Trimesters of Pregnancy.
Al Mansour L, Tylski P, Chene G, Plaisant F, Janier M, Bolze PA, You B, Defez D, Tordo J, Flaus A.
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.
Perez-Fidalgo A, Schmalfeldt B, George A, Gourley C, Pignata S, Lorusso D, Barretina-Ginesta MP, Romero I, Grimm C, Van Gorp T, Rossing M, Collins DC, Fernebro J, Bjørge L, Leary A, de la Motte Rouge T, Harter P, Kurzeder C, Savva-Bordalo J, You B.
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
Corbaux P, Colomban O, Carrot A, You B.
Uterine transarterial embolization as nonsurgical management for uterine rupture following vaginal delivery: A report of two cases.
Grange R, Digonnet LE, Mayaud A, Chauleur C, Boutet C, Raia-Barjat T, Grange S.
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia.
Msika A, Mathias V, Boudigou M, Chambon M, Dubois V, Hajri T, Lotz JP, Massardier J, Descargues P, Gladieff L, Joly F, Lebreton C, Maucort-Boulch D, Bin S, Rousset P, Allias F, Gaillot-Durand L, Devouassoux-Shisheboran M, Lemaitre N, Alfaidy N, Langlois-Jacques C, Alves-Ferreira M, Golfier F, You B, Thaunat O, Bolze PA, Koenig A.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators.